Continuous glucose monitoring as equinox of nocturnal and daytime hypoglycaemia in type 1 diabetes: insights from the randomized controlled HypoDE trial
CGM effectively reduced nocturnal and daytime hypoglycaemia. Without CGM, nocturnal hypoglycaemia contributes to daytime risks, while daytime hypoglycaemia elevates SH risk. Expanding CGM access and addressing nocturnal hypoglycaemia in resource-limited settings are critical. TrialregistrationClinicaltrials.gov: NCT02671968.
Authors
- Dominic Ehrmann (ORCID: https://orcid.org/0000-0002-5794-5596)
- Malte Jacobsen (ORCID: https://orcid.org/0000-0003-0780-0003)
- Lutz Heinemann (ORCID: https://orcid.org/0000-0003-2493-1304)
- Bernhard Kulzer (ORCID: https://orcid.org/0000-0001-9120-4479)
- Norbert Hermanns (ORCID: https://orcid.org/0000-0002-2903-2677)
- Arne Schäfer (ORCID: https://orcid.org/0000-0001-6600-3691)
Institutions
- RWTH Aachen University (DE)
Publication Details
- Journal
- Diabetes Research and Clinical Practice
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1016/j.diabres.2025.112228
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Dexcom
- Roche Diabetes Care